McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
Lewis CJ. Letter to reiterate certain public health and safety concerns to firms manufacturing or importing dietary supplements that contain specific bovine tissues. FDA. Available at: www.cfsan.fda.gov/~dms/dspltr05.html.
Murray MT. Encyclopedia of Nutritional Supplements. Rocklin, CA: Prima Health, 1996.
Nationwide alert on hallmark labs injectable adrenal cortex extract. FDA. Available at: www.fda.gov/bbs/topics/NEWS/NEW00539.html
La Marca G, Pumilia G, Martino A. [Effectiveness of mesoglycan topical treatment of leg ulcers in subjects with chronic venous insufficiency]. Minerva Cardioangiol 1999;47:315-9.
Laurora G, Cesarone MR, Belcaro G, et al. [Control of the progress of arteriosclerosis in high risk subjects treated with mesoglycan. Measuring the intima media]. Minerva Cardioangiol 1998;46:41-7.
Raso AM, Maggio D, Trogolo M, et al. [Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol]. Minerva Cardioangiol 1997;45:383-92.
Scondotto G, Catena G, Aloisi D. [Use of mesoglycan in venous pathology]. Minerva Med 1997;88:537-41.
Blardi P, Messa G, Puccetti L, et al. [Effects on the coagulation-fibrinolysis system of a single oral dose of mesoglycan at the beginning and at the end of a prolonged treatment in man]. Recenti Prog Med 1995;86:282-9.
Vecchio F, Zanchin G, Maggioni F, et al. Mesoglycan in treatment of patients with cerebral ischemia: effects on hemorheologic and hematochemical parameters. Acta Neurol (Napoli) 1993;15:449-56.
Lotti T, Celasco G, Tsampau D, et al. Mesoglycan treatment restores defective fibrinolytic potential in cutaneous necrotizing venulitis. Int J Dermatol 1993;32:368-71.
Ambrosio LA, Marchese G, Filippo A, et al. The effect of mesoglycan in patients with cerebrovascular disease: a psychometric evaluation. J Int Med Res 1993;21:138-46.
Orlandi G, Viapiano F, Massetani R, et al. Clinical-instrumental evaluation of the effects of mesoglycan sulphate in chronic vascular encephalopathy. Acta Neurol (Napoli) 1991;13:255-60.
Agrati AM, De Bartolo G, Palmieri G. [Heparan sulfate: efficacy and safety in patients with chronic venous insufficiency]. Minerva Cardioangiol 1991;39:395-400.
Abate G, Berenga A, Caione F, et al. [Controlled multicenter study on the therapeutic effectiveness of mesoglycan in patients with cerebrovascular disease]. Minerva Med 1991;82:101-5.
Prandoni P, Cattelan AM, Carta M. [Long-term sequelae of deep venous thrombosis of the legs. Experience with mesoglycan]. Ann Ital Med Int 1989;4:378-85.
Cazzato G, Zorzon M, Mase G, et al. [Mesoglycan in acute focal cerebral ischemia]. Riv Neurol 1989;59:121-6.
Vittoria A, Messa GL, Frigerio C, et al. Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses. Int J Tissue React 1988;10:261-6.
Andreozzi GM, Signorelli S, Lo Duca S, et al. Effects of mesoglycan sulfate on the arterial elastic module. Angiology 1987;38:593-600.
Petruzzellis V, Velon A. [Therapeutic action of oral mesoglycan in the pharmacologic treatment of the varicose syndrome and its complications]. Minerva Med 1985;76:543-8.
Scondotto G, De Fabritiis A, Guastarobba A, et al. [Use of a minor fibrinolytic drug (mesoglycan) in phlebitis]. Minerva Med 1984;75:1733-8.
Postiglione A, De Simone B, Rubba P, et al. Effect of oral mesoglycan on plasma lipoprotein concentration and on lipoprotein lipase activity in primary hyperlipoproteinemia. Pharmacol Res Commun 1984;16:1-8.
Arosio E, Ferrari G, Santoro L, et al. A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers. Eur J Vasc Endovasc Surg 2001;22:365-72.
Nenci, G. G., Gresele, P., Ferrari, G., Santoro, L., and Gianese, F. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study. Thromb.Haemost. 2001;86(5):1181-1187.
Bettini, R., Maino, C., and Gorini, M. [Effectiveness of mesoglycan in the prevention of cerebral ischemia]. Clin.Ter. 2003;154(1):13-16.
Mansi, D., Sinisi, L., De Michele, G., Di Geronimo, G., Palma, V., Brescia, Morra, V, Coppola, N., and Buscaino, G. A. Open trial of mesoglycan in the treatment of cerebrovascular ischemic disease. Acta Neurol.(Napoli) 1988;10(2):108-112.
Tardieu, M., Bourin, M. C., Desgranges, P., Barbier, P., Barritault, D., and Caruelle, J. P. Mesoglycan and sulodexide act as stabilizers and protectors of fibroblast growth factors (FGFs). Growth Factors 1994;11(4):291-300.
Messa, G., Blardi, P., La Placa, G., Puccetti, L., and Ghezzi, A. [Effects of 2 single oral doses of mesoglycan on the coagulation-fibrinolysis system in man. A pharmacodynamic study]. Recenti Prog.Med. 1995;86(7-8):272-281.
Laurora, G., Ambrosoli, L., Cesarone, M. R., De Sanctis, M. T., Incandela, L., Marelli, C., and Belcaro, G. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study. Panminerva Med. 1994;36(2):83-86.
Laurora, G., Cesarone, M. R., De Sanctis, M. T., Incandela, L., and Belcaro, G. Delayed arteriosclerosis progression in high risk subjects treated with mesoglycan. Evaluation of intima-media thickness. J.Cardiovasc.Surg.(Torino) 1993;34(4):313-318.
Giorgetti, P. L., Marenghi, M. C., and Bianciardi, P. [Heparan sulfate in the therapy of postphlebitic syndrome. Evaluation of the efficacy and tolerability as compared to mesoglycan]. Minerva Cardioangiol. 1997;45(6):279-284.
Pacella E, Pacella F, Turchetti P, et al. A pilot clinical study on the effectiveness of mesoglycan against diabetic retinopathy. Clin Ter. 2012;163(1):19-22.
Viliani T, Scarselli M, Pieri A, Gatti M, Santini M, Pasquetti P. Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan. Eur J Phys Rehabil Med. 2009;45(1):21-9.
Gossetti B, Antignani PL, Jabbour J, Martinelli O. Flow-mediated dilation benefits of mesoglycan in peripheral artery disease. Int Angiol. 2015;34(4):398-406.
Duque-Estrada B, Vincenzi C, Misciali C, Tosti A. Alopecia secondary to mesotherapy. J Am Acad Dermatol. 2009;61(4):707-9.
Gallo G, Mistrangelo M, Passera R, et al. Efficacy of mesoglycan in pain control after excisional hemorrhoidectomy: a pilot comparative prospective multicenter study. Gastroenterol Res Pract. 2018;2018:6423895.
Neri G, Marcelli V, Califano L, Glicover Investigators. Assessment of the effect of mesoglycan in the treatment of audiovestibular disorders of vascular origin. Int J Immunopathol Pharmacol. 2018;32:2058738418773833.
Valvano A, Bosso G, Apuzzi V, Riccone F, Saccá L, Oliviero U. Mesoglycan improves vascular reactivity and insulin sensitivity in patients with metabolic syndrome. Atherosclerosis. 2015;243(2):407-13.
Gallo G, Di Saverio S, Clerico G, et al. Mesoglycan for pain control after open excisional haemorrhoidectomy (MeHAEMO): an observational multicentre study on behalf of the Italian Society of Colorectal Surgery (SICCR). BMC Surg. 2020 Oct 22;20(1):251.